Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MAGR posted to hotstockchat.com 10:28 AM
TYRIA distributor licensed for Wal-Mart, Costco, Fred Meyer
and BJ's. (my addition to 9:45 AM release)
EFCR posted to hotstockchat.com 10:28 AM
DWOG up 19% , big spread though
SFXC - Chart Newbie - sorta
Reminder: Check For: ---> Dilution - Splits - News
SFXC up 62%
CCCN up 26%
TTCS changed to TNOG
SAN ANTONIO, TX, USA, Feb 25, 2005 (M2 PRESSWIRE via COMTEX) -- Titan
Consolidated, Inc. (TTCS:OTC) reports that the Company name has been changed,
effective immediately, to Titan Oil and Gas, Inc.
Titan CEO Kent Jacobson reports: "As of the market open on Friday, February 25,
2005, Titan Oil and Gas, Inc., will be trading under a new symbol, TNOG:OTC."
hi all bit busy here, brb
WPRO - Chart
Reminder: Check For: ---> Dilution - Splits - News
VYST - Chart
Reminder: Check For: ---> Dilution - Splits - News
USVO - Chart
Reminder: Check For: ---> Dilution - Splits - News
TTCS - Chart Newbie
Reminder: Check For: ---> Dilution - Splits - News
I was thinking the same thing market!
MBTT - Chart
Reminder: Check For: ---> Dilution - Splits - News
IVFH - Chart
Reminder: Check For: ---> Dilution - Splits - News
GCCP - Chart
Reminder: Check For: ---> Dilution - Splits - News
FMDAY - Chart Newbie
Reminder: Check For: ---> Dilution - Splits - News
EMDF - Chart
Reminder: Check For: ---> Dilution - Splits - News
DWOG - Chart
Reminder: Check For: ---> Dilution - Splits - News
DCUT - Chart Newbie
Reminder: Check For: ---> Dilution - Splits - News
CNES - Chart
Reminder: Check For: ---> Dilution - Splits - News
CIRT - Chart
Reminder: Check For: ---> Dilution - Splits - News
BIPH - Chart
Reminder: Check For: ---> Dilution - Splits - News
ABTG - Chart
Reminder: Check For: ---> Dilution - Splits - News
hi m !
NEOP announced financial results for fourth quarter 2004
DUBLIN, Ohio--(BUSINESS WIRE)--Feb. 24, 2005--
Neoprobe Corporation (OTCBB:NEOP) today announced
financial results for the fourth quarter of 2004 and for the full year
that ended December 31, 2004. Results for the fourth quarter and for
the full year of 2004 include the consolidated operations of Neoprobe
Corporation and its wholly owned subsidiary, Cardiosonix Ltd. For the
fourth quarter of 2004, Neoprobe had a net loss of $2.3 million
(including total non-cash expenses of $1.6 million) or $0.04 per
share. For fiscal year 2004, Neoprobe incurred a net loss of $3.5
million (including total non-cash expenses of $2.3 million) or $0.06
per share.
For the year 2004, Neoprobe reported total revenues of $6.0
million compared to $6.5 million in the prior year. Gross profit for
2004 increased $223,000 or 7% in 2004 as compared to 2003 despite the
9% decline in total revenue over the same periods. However, license
and other revenues for 2003 included the recognition of $800,000 in
non-cash license revenue and $145,000 in reimbursed research and
development whereas license and other revenues for 2004 included only
$600,000 of non-cash license revenue. Excluding license and other
revenue, gross profit on net sales of our medical devices increased
$568,000 or 23% over the prior year despite the decline in sales. For
the fourth quarter of 2004, Neoprobe reported total revenues of $1.3
million compared to $1.9 million for the fourth quarter of 2003.
The improvement in gross profit in 2004 is a reflection of our
ongoing strategy to innovate and leverage off our medical device
businesses as we invest in the potential of our radiopharmaceutical
development initiatives, Lymphoseek(TM) and RIGScan(R) CR. Overall,
Neoprobe's research and development expenses for 2004 increased to
$2.5 million compared to $1.9 million in 2003 due primarily to the
$440,000 in incremental costs incurred in 2004 related to our
radiopharmaceutical initiatives as compared to 2003. General and
administrative expenses remained steady at $3.2 million for 2004
compared to $3.1 million for 2003.
"Our gamma device line continues to show strong revenue
performance and the 23% improvement in our device product margins
reinforces the underlying importance of this product line to our
business plan. We expect the positive results from our gamma device
line to be supplemented in the near future by sales of our
Quantix/OR(TM) blood flow measurement device based on the recent
receipt of marketing clearances for the device in the U.S. and the
European Union," said David Bupp, Neoprobe's President and CEO. "The
financial strength we have gained from our recent financing, coupled
with the revenue generation capabilities of our medical device
businesses, has provided us with the financial foundation to invest in
promising technologies and support the achievement of our goals over
the next few years. We believe Neoprobe is now in a position to
maximize its business potential," Bupp added.
The net loss for the fourth quarter and for the year included $1.3
million in non-cash interest expense resulting from the accounting
treatment for the private placement we completed in December 2004.
Current generally accepted accounting principles require that the
warrants issued in connection with the placement be classified as a
liability due to provisions contained in the securities purchase
agreement. As a liability, the warrants are considered a derivative
instrument that must be periodically "marked to market" on our balance
sheet. Because the value of our stock increased $0.19 per share
between the closing date of the financing on December 14, 2004 and
December 31, 2004, our year end, the effect of marking the warrant
liability to market resulted in an additional $1.2 million of non-cash
expense during the fourth quarter of 2004. Subsequent to December 31,
2004, the Company and the investor have confirmed in writing their
intention that the penalty provisions which led to this accounting
treatment were intended to apply only to the $8.1 million principal
balance of the promissory notes and underlying conversion shares and
not to the warrant shares. As such, the Company intends to reclassify
the estimated fair value of the warrant liability to additional paid
in capital during the first quarter of 2005.
Neoprobe's President and CEO, David Bupp, and Vice President and
CFO, Brent Larson, will provide a business update and discuss the
Company's 2004 results via a conference call scheduled for 11:00 AM
EST tomorrow, Friday, February 25, 2005. Participants may dial-in by
calling 1-888-823-7457 from the United States and Canada or by calling
1-973-582-2718 internationally. A replay of the call will be available
for one week by calling 1-877-519-4471 (PIN# 5754372) from the United
States and Canada or by calling 1-973-341-3080 internationally.
just call me 'e', lee, or eed whatever suits you ;()
MAGR GJ bob, looks great on close too
EFCR may still have legs for tomorrow
little busy here with other stuff, brb
MRKL me either, got in at .53 and out at .55
looks better now than when the news buyers jumped in, boards picked upa bit late on it.
11:41 AM, which can seem old sometimes
MRKL - Chart
Reminder: Check For: ---> Dilution - Splits - News
MRKL U.S. Army's Night Vision and Electronic Sensors Directorate (NVESD) has awarded the
Company new orders for technology products and services totaling $2.0
million. Robert Tarini, Chairman and CEO of Markland, made the
announcement.
The Army's NVESD research and development group is one of the U.S.
military's most advanced technological leaders. Markland is working on
a range of next-generation technology solutions for the NVESD,
including night vision and advanced sensor applications, disposable
sensors and other threat-detection systems.
The $2.0 million in new orders come under a five-year omnibus
contract. The sales revenues derived from these new orders will be
realized over a 12-month performance period. This will bring the total
dollars awarded to EOIR Technologies Inc., a wholly-owned subsidiary
of Markland, on this NVESD Omnibus contract since July 1, 2004, to
approximately $45.9 million.
The ongoing five year omnibus contract may provide a maximum
ceiling amount of up to $80 million in fiscal year revenues for
Markland. The contract has a potential value of approximately $406
million over the life of the contract.
"Our core business is moving along extremely well having achieved
approximately $33M in fiscal six month sales revenues," said Mr.
Tarini. "We believe that our recent purchase of Genex Technolgies and
formation of a public subsidiary has created shareholder value. Genex
Technologies expertise in intelligent 3D surveillance and disposable
sensor technology is very synergistic and offers significant revenue
growth opportunities. We believe that a number of our research and
development programs offer great promise in the areas of remote
detection of suicide bombers and chemical detection and that our
second half of the fiscal year will continue our recent trends in
revenue capture."
Many of the products and services being delivered on this contract
utilize next-generation electro-optic and infrared sensor technologies
that are being used in direct support of U.S. military combat
operations in Iraq, Afghanistan and elsewhere. The Army's NVESD has
been responsible for numerous key innovations in the fields of optical
electronics and thermal imaging for weapons targeting, electronic
surveillance and other mission-critical military appl
heh I was watching acup too, and took it off my list a day ago ;()
MMFS - Chart - Watching
Reminder: Check For: ---> Dilution - Splits - News
Only made one buy this morning, the right one :)
MAGR nice mover